News | August 26, 2008

CYPHER SELECT Plus Sirolimus-Eluting Coronary Stent Receives CE Mark for Heart Attacks

August 27, 2008 - Cordis Corp. today said it received CE mark approval to market the CYPHER SELECT Plus Sirolimus-eluting coronary stent for the treatment of acute myocardial infarction (AMI).

CE mark approval means the product has been deemed safe and effective for treatment of AMI and can now be promoted for this indication in all member states of the European Union (EU), European Economic Area and Switzerland.

The expanded indication for the CYPHER SELECT Plus stent provides physicians with another option for treating this serious cardiac event, the company said. According to Working Group on Interventional Cardiology of the European Society of Cardiology and European Association of Percutaneous Cardiovascular Interventions, more than 150,000 percutaneous coronary interventions are performed for heart attacks every year in Europe. (EuroIntervention; 2007; 3: 442-446).

The expanded indication for the CYPHER SELECT Plus in the EU is based on several scientific publications providing clinical evidence for this indication, especially data from TYPHOON (Trial to Assess the use of the CYPHER Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty), the first randomized, multi-center clinical trial to study the safety and efficacy of the CYPHER in patients who suffered a heart attack.

In TYPHOON, the CYPHER stent reduced the risk of target vessel failure (TVF) by almost half in patients who suffered a heart attack compared to those who were treated with a bare metal stent (BMS) (7.3 percent for the CYPHER vs. 14.3 percent for the BMS arm; (p

In addition, the overall mortality rate in both the CYPHER Stent arm of the trial and the BMS arm was low (2.2 percent in both).

“No other drug-eluting stent has this level of clinical data support in the setting of primary angioplasty for acute myocardial infarction,” said Christian Spaulding, M.D., FACC, professor of cardiology, Assistance Publique-Paris University Hospitals, Paris, France, Cordis consultant and lead author of the TYPHOON study. “More than 3,000 patients have been included in nine randomized trials to assess the safety and efficacy of the CYPHER SELECT Plus stent in AMI. All of these studies have demonstrated significant reductions in the occurrence of repeat revascularization at one year with no increase in stent thrombosis, death or repeat myocardial infarction.”

The TYPHOON trial was conducted at 48 sites across Europe, Israel and Australia. Clinical trial data were initially presented at the American College of Cardiology annual scientific session in March 2006 and the data also appeared in the New England Journal of Medicine in September 2006.

CYPHER stents have been used in more than three million patients worldwide.

The CYPHER SELECT Plus Stent is not approved or available for sale in the U.S.

For more information: www.cordis.com

Related Content

The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents| November 24, 2017
November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting, presente
News | Stents| November 10, 2017
Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now...
OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

Feature | Stents| November 08, 2017
November 8, 2017 – New results from the HARMONEE Japan/U.S.
FDA Approves COBRA REDUCE Trial of 14-Day DAPT With CeloNova Stent
News | Stents| October 27, 2017
CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion of CeloNova's...
CeloNova Cobra Pzf stent
Technology | Stents| March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents| January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
EXCEL Trial, TCT 2016, drug-eluting stents, CABG, surgery left main heart disease, LMCAD

Gregg W. Stone, M.D., presenting the EXCEL data at TCT 2016 during a standing room only late-breaking trial session.

Feature | Stents| January 12, 2017 | Dave Fornell
The biggest news from the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting this past fall was the results
Biotronik's Osiro stent, prison IV trial

Biotronik's Osiro ultra-thin strut, sirolimus-eluting stent.

News | Stents| November 09, 2016
November 9, 2016 – Results from a randomized, multicenter trial failed to show non-inferiority of hybrid, ultra-thin
OCT stent strut coverage

OCT imaging showing neointimal tissue coverage of metallic stent struts.

News | Stents| November 07, 2016
November 7, 2016 – Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
biosensors Biofreedom stent
News | Stents| November 07, 2016
November 7, 2016 – The two-year results from LEADERS FREE, the first randomized clinical trial dedicated to high blee
Overlay Init